Background-Angiotensin converting enzyme (ACE) inhibition after myocardial infarction is associated with an improvement in plasma fibrinolytic parameters. The aim of the present study was to determine whether acute ACE inhibition and angiotensin II type 1 (AT 1 ) receptor antagonism have similar effects in patients with heart failure. Methods and Results-Twenty patients with moderately severe chronic heart failure received enalapril 10 mg and losartan 50 mg on 2 separate occasions in a single-blind, randomized, crossover design. Plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) antigen and activity were measured at baseline and 6 hours after the dose. Acute administration of losartan but not of enalapril reduced plasma t-PA (11%; Pϭ0.003) and PAI-1 (38%; PϽ0.001) antigen concentrations, which was associated with increases in t-PA (29%; Pϭ0.03) and decreases in PAI-1 (48%; Pϭ0.01) activity. Changes in plasma fibrinolytic parameters were more marked during losartan treatment (PϽ0.02), with a 3-fold greater reduction in plasma PAI-1 antigen concentrations (PϽ0.05). Conclusions-Acute AT 1 antagonism in patients with heart failure is associated with a significant improvement in plasma fibrinolytic parameters that is greater than during ACE inhibition. These beneficial effects of AT 1 antagonism and ACE inhibition would therefore appear to be mediated principally through suppression of angiotensin II. (Circulation. 1999;99:2983-2985.)
I
t would be anticipated that high tissue plasminogen activator ( t-PA) concentrations would protect against subsequent coronary events. However, paradoxically, epidemiological studies of total t-PA (antigen) concentrations in patients with ischemic heart disease 1,2 have observed a positive correlation with future coronary events. This may be explained by the concomitant elevation of plasminogen activator inhibitor type 1 (PAI-1), which complexes with t-PA and therefore causes an overall reduction in free t-PA "activity." 3, 4 It is this free and unbound t-PA that is physiologically active and leads to endogenous fibrinolysis.
Several large-scale heart failure and post-myocardial infarction trials ( 6 are known to induce the release of PAI-1 and t-PA, respectively, the benefits of ACE inhibitor therapy may be mediated through increases in bradykinin-induced t-PA release or a reduction in angiotensin II-mediated PAI-1 release or both. Indeed, the use of ACE inhibitors after myocardial infarction is associated with a decrease in PAI-1 concentrations and a potential increase in t-PA activity. 7, 8 However, the effects of ACE inhibition on plasma fibrinolytic factors have not been assessed in patients with heart failure, and it is unknown whether these beneficial effects are also seen with angiotensin II type 1 (AT 1 ) receptor antagonism. The aim of the present study, therefore, was to determine whether acute ACE inhibition and AT 1 receptor antagonism have similar effects in patients with heart failure.
Methods

Subjects
Twenty patients with New York Heart Association (NYHA) grade II to III chronic heart failure and objective evidence of left ventricular impairment (left ventricular ejection fraction Ͻ40%, shortening fraction Ͻ20%, or left ventricular end-diastolic diameter Ͼ5.5 cm) were recruited with the approval of the local research ethics committee and in accordance with the Declaration of Helsinki. The written informed consent of each subject was obtained before entry into the study. No patient had previously received ACE inhibitor or AT 1 receptor antagonist therapy or had a myocardial infarction within 3 months of the study. Concomitant therapy was omitted on the day of attendance.
Measurements
Supine heart rate and blood pressure were monitored at intervals throughout each study with a semiautomated, noninvasive oscillometric sphygmomanometer 9 (Takeda UA 751, Takeda Medical Inc).
Ten milliliters of blood was withdrawn from the antecubital fossa of the forearm and collected into acidified buffered citrate (Biopool Stabilyte for t-PA assays) and citrate (Monovette for PAI-1 assays) tubes and kept on ice before being centrifuged at 2000g for 30 minutes at 4°C. Platelet-free plasma was decanted and stored at Ϫ80°C before assay. 10 Plasma PAI-1 and t-PA antigen and activities and atrial natriuretic peptide (ANP) concentrations were determined by ELISAs and a photometric method as previously described. 11, 12 All assays were performed by blinded independent operators.
Study Design
Patients attended the clinic at 9 AM and rested recumbent for 20 minutes before measurements were made. At 10 AM, patients received a single-blind, randomized oral dose of enalapril 10 mg or losartan 50 mg followed by a light lunch at midday. After an additional 20-minute period of supine rest at 4 PM, repeated measurements were taken to coincide with peak plasma concentrations of the active metabolites (enalaprilat and E3174, respectively). To allow for a sufficient washout of enalaprilat and E3174, patients reattended 2 days later to undergo the same protocol but crossed over to receive the alternate therapy.
Data Analysis and Statistics
Data were examined by ANOVA and 2-tailed paired Student's t test with Excel version 5.0 (Microsoft). All results are expressed as meanϮSEM. Statistical significance was taken at the 5% level.
Results
Patient characteristics are shown in Table 1 . Baseline predose hemodynamic, plasma ANP, and fibrinolytic parameters were similar on the 2 study days, with no significant differences ( Table 2) or time order effects.
After losartan therapy, plasma t-PA and PAI-1 antigen concentrations fell by 11% (Pϭ0.003) and 38% (PϽ0.001), respectively (Table 2; Figure) . Plasma t-PA activity increased by 29% (Pϭ0.03), whereas PAI-1 activity fell by 48% (Pϭ0.01). Enalapril therapy was associated with similar changes in fibrinolytic parameters (Ϫ6%, Ϫ14%, 21%, and Ϫ17%, respectively), but they were not statistically significant (Pϭ0.1 to 0.4). Changes in plasma fibrinolytic parame- Changes in plasma t-PA (white bars) and PAI-1 (black bars) antigen (solid bars) and activity (hatched bars) after single oral dose of enalapril and losartan in patients with heart failure. *Pϭ0.016 (2-way ANOVA for changes in 4 plasma fibrinolytic parameters; losartan vs enalapril); †Pϭ0.047 (t test for changes in plasma PAI-1 antigen; losartan vs enalapril).
ters were more marked during losartan treatment (Pϭ0.016; 2-way ANOVA, enalapril versus losartan), with a 3-fold greater reduction in plasma PAI-1 antigen concentrations (Pϭ0.047; t test, enalapril versus losartan). There were no significant effects on plasma ANP concentrations (Table 2) .
Discussion
We have shown that acute AT 1 receptor antagonism in patients with heart failure is associated with a significant improvement in plasma fibrinolytic parameters. Moreover, this improvement was greater than with ACE inhibition, which suggests that these effects are mediated directly through suppression of angiotensin II. Previous studies have shown the beneficial effects of ACE inhibition on fibrinolytic parameters in patients after an acute myocardial infarction. 7, 8 In the present study, we assessed the acute effects in patients with heart failure, and our results are consistent with these post-myocardial infarction studies. This suggests that the benefits of ACE inhibition are not limited to the immediate postinfarction period but may also be achieved in patients with heart failure. Additionally, we have directly assessed t-PA activity and have confirmed that the changes in basal t-PA and PAI-1 antigen concentrations are associated with an increase in t-PA activity.
It has been suggested that the changes in fibrinolytic parameters seen with ACE inhibitors may be mediated through augmentation of bradykinin, because t-PA release is induced by bradykinin infusions during systemic ACE inhibition. 6 However, the present study would suggest that bradykinin is not involved in basal t-PA release because of the similar effects of AT 1 receptor antagonism on the profile of plasma t-PA and PAI-1 concentrations. Moreover, given the greater efficacy of AT 1 receptor antagonism, particularly on PAI-1 concentrations, it would appear that angiotensin II is the principal mediator of this effect. This is consistent with the in vitro 13 and in vivo 5 release of PAI-1 with angiotensin II administration. Furthermore, these observations may provide one potential explanation for the findings of the ELITE [Evaluation of Losartan in The Elderly] study, in which AT 1 receptor antagonism was associated with reduced mortality compared with ACE inhibition in patients with heart failure. 14 Plasma t-PA and PAI-1 concentrations undergo diurnal variations, which have a complementary and inverse sinusoidal relationship. 15 Such diurnal variation may contribute in part to the observed changes in fibrinolytic parameters, although this does not explain the differential effects of ACE inhibition and AT 1 receptor antagonism, especially on PAI-1. In addition, the doses of losartan 14 and enalapril 16 were chosen on the basis of the major published heart failure trials, and the observed differences are unlikely to reflect a dose effect because the resultant hemodynamic effects were similar.
In conclusion, the present study suggests that in patients with heart failure, acute angiotensin II inhibition with AT 1 receptor antagonism produces a marked improvement in basal fibrinolytic balance through a reduction in PAI-1.
